Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Pivot

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJ Gligorov, B Ataseven, M Verrill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2008
Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence studyL Chaigneau, B Royer, D Montange, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-upL Zelek, A Llombart-Cussac, P Terrier, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2011
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclinesE Curtit, P Nouyrigat, N Dohollou, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapyN Magné, X Pivot, R J Bensadoun, et al.
Breast (Edinburgh, Scotland)|August 10, 2010
Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impactA Thiery-Vuillemin, A Llombart-Cussac, L Chaigneau, et al.
Oncology Reports|April 18, 2000
A multivariate analysis for predicting cisplatin-induced delayed emesisX Pivot, N Marghali, M C Etienne, et al.
Oncology|January 11, 2001
Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neckX Pivot, L Cals, D Cupissol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyC Jackisch, S-B Kim, V Semiglazov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancerX Pivot, S Wadler, C Kelly, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|June 20, 2017
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJ Gligorov, B Ataseven, M Verrill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2008
Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence studyL Chaigneau, B Royer, D Montange, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-upL Zelek, A Llombart-Cussac, P Terrier, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2011
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclinesE Curtit, P Nouyrigat, N Dohollou, et al.
European Journal of Cancer (Oxford, England : 1990)|October 26, 2001
The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapyN Magné, X Pivot, R J Bensadoun, et al.
Breast (Edinburgh, Scotland)|August 10, 2010
Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impactA Thiery-Vuillemin, A Llombart-Cussac, L Chaigneau, et al.
Oncology Reports|April 18, 2000
A multivariate analysis for predicting cisplatin-induced delayed emesisX Pivot, N Marghali, M C Etienne, et al.
Oncology|January 11, 2001
Phase II trial of a paclitaxel-carboplatin combination in recurrent squamous cell carcinoma of the head and neckX Pivot, L Cals, D Cupissol, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 19, 2014
Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyC Jackisch, S-B Kim, V Semiglazov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 2, 2002
Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancerX Pivot, S Wadler, C Kelly, et al.
Pageof 10